Has Catherine Small, MD received payments from drug or device companies?

Yes. Drug and device makers reported $2,221 in general payments to Catherine Small, MD across 4 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Catherine Small, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Catherine Small, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Catherine Small, MD

Infectious Disease · Valhalla, NYNPI 1881617520

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $1,357 of the $2,221 with a category attached, or 61.1%. Partner Therapeutics, Inc. accounts for 61.1% of it on its own, with 1 other manufacturer making up the rest. Reporting peaked in 2022 at $1,357 and has fallen 98.6% since, to $19 in 2024.

$2,221in general payments, 2019–2025

Across 4 payments — averaging $555.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Partner Therapeutics, Inc.$1K
Gilead$864

$2,684,430in research payments, 2019–2025

Across 318 payments — averaging $8441.60 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Gilead$1.1M
Merck$1.1M
Karyopharm Therapeutics Inc.$167K
Shire North American Group Inc$127K
Takeda Pharmaceuticals U.S.A., Inc.$48K
GSK$45K
plus $57K from 2 others

What the payments were for

Consulting fees$84038%
Speaking & faculty fees$1,35761%
Food & beverage$241%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Partner Therapeutics, Inc.	1	$1,357
Gilead	3	$864

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

Leukine$1,357
Veklury$840

How this compares

$2,221 in reported general payments places this provider in the 80th percentile of 799 infectious disease providers in New York.

See all infectious disease providers in New York →

Medicare billing

Part B allowed, 2024

$46,187

Medicare patients

Services billed

365

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala	24	$87,593
TriumeqAbacavir/Dolutegravir/Lamivudi	12	$52,078
GenvoyaElviteg/Cob/Emtri/Tenof Alafen	12	$47,011

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

Company	Paid to this provider	Part D cost of their drugs
GileadBiktarvy, Genvoya	$864	$134,60436 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 799 infectious disease providers in New York.

Other infectious disease in Valhalla

Abhay DhandValhalla$201K
Harish MoorjaniBriarcliff Manor$733K
Sorana Segal MaurerFlushing$598K
Sian JonesNew York$406K
Antonio UrbinaNew York$373K
David BekhorNew York$358K
Andre BrutusBrooklyn$303K
Stephen ThomasSyracuse$294K
Glenn TurettFlushing$253K
Genovefa PapanicolaouNew York$209K

See the full list for New York →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →